Pfizer has obtained breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Xalkori (crizotinib) to treat patients with ROS1-positive non-small cell lung cancer (NSCLC).
ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC, which is said to occur in 1% of NSCLC cases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pfizer oncology chief medical officer and clinical development and medical affairs senior vice-president Dr Mace Rothenberg said: "We are excited that the FDA has granted breakthrough therapy designation for xalkori as a potential treatment for patients with ROS1-positive NSCLC.
"Xalkori pioneered precision medicine for ALK-positive metastatic NSCLC, and ROS1 represents a second molecular subgroup of NSCLC in which Xalkori has demonstrated a level of anti-tumour activity that can potentially make a real difference for patients."
The designation has been provided based on a data from an expansion cohort of a global Phase I trial, Study 1001, which assessed Xalkori in 50 patients with ROS1-positive advanced NSCLC.
According to the company, the study demonstrated that Xalkori exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataXalkori already received FDA approval to treat patients with metastatic NSCLC whose tumours are anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.
It obtained approval in around ten countries, including Australia, Canada, China, Japan, South Korea and the European Union.
Image: Pfizer world headquarters. Photo: courtesy of Norbert Nagel, Mörfelden-Walldorf, Germany.
